The new Phase III study will test calderasib in a chemo-free regimen for G12C-mutated patients regardless of PD-L1 status.
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback